Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial

Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial

Background In CheckMate 9LA, nivolumab plus ipilimumab with chemotherapy prolonged overall survival (OS) versus chemotherapy regardless of tumor PD-L1 expression or histology. We report updated efficacy and safety in all randomized patients with a minimum 4-year follow-up and an exploratory treatmen...

Full description

Bibliographic Details
Main Authors: Enriqueta Felip, David P. Carbone, Martin Reck, Luis Paz-Ares, Yong Yuan, Nan Hu, Niels Reinmuth, Xiaoqing Zhang, Thomas John, Ying Cheng, Shun Lu, Manuel Cobo, Michael Schenker, Tudor-Eliade Ciuleanu, Stéphanie Bordenave, Oscar Juan-Vidal, Juliana Menezes, Eduardo Richardet, Hideaki Mizutani, Bogdan Zurawski, Aurelia Alexandru, Javed Mahmood, Tuli De, Irene Santi, John R. Penrod, Adam Lee
Format: Article
Language:English
Published: BMJ Publishing Group 2024-02-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/12/2/e008189.full

Internet

https://jitc.bmj.com/content/12/2/e008189.full

Similar Items